作者: Antunes, Felipe Antonio Fernandes ; Rocha, Thiago Moura ; Dos Santos, Júlio César ; Marcelino, Paulo Ricardo Franco ; Sánchez-Muñoz, Salvador ; da Silva, Silvio Silvério

The replacement of agrochemicals by biomolecules is imperative to mitigate soil contamination and inactivation of its core microbiota. Within this context, this study aimed at the interaction between a biological control agent such as Trichoderma harzianum CCT 2160 (BF-Th) and the biosurfactants (BSs) derived from the native Brazilian yeast Starmerella bombicola UFMG-CM-Y6419. Thereafter, their potential in germination of Oryza sativa L. seeds was tested. Both bioproducts were produced on site and characterized according to their chemical composition by HPLC-MS and GC-MS for BSs and SDS-PAGE gel for BF-Th. The BSs were confirmed to be sophorolipids (SLs) which is a well-studied compound with antimicrobial activity. The biocompatibility was examined by cultivating the fungus with SLs supplementation ranging from 0.1 to 2 g/L in solid and submerged fermentation. In solid state fermentation the supplementation of SLs enhanced spore production, conferring the synergy of both bioproducts. For the germination assays, bioformulations composed of SLs, BF-Th and combined (SLT) were applied in the germination of O. sativa L seeds achieving an improvement of up to 30% in morphological aspects such as root and shoot size as well as the presence of lateral roots. It was hypothesized that SLs were able to regulate phytohormones expression such as auxins and gibberellins during early stage of growth, pointing to their novel plant-growth stimulating properties. Thus, this study has pointed to the potential of hybrid bioformulations composed of biosurfactants and active endophytic fungal spores in order to augment the plant fitness and possibly the control of diseases.

2024-03-01·Annals of Pharmacotherapy

Physical and Chemical Compatibility of Medications Commonly Used in Critically Ill Patients With Balanced Crystalloids: A Systematic Review

Review

作者: Duggal, Abhijit ; Stollings, Joanna L. ; Farrar, Julie E. ; Bauer, Seth R. ; Buckley, Christopher T. ; Schleicher, Mary

Objective: Evaluate available evidence of physical and/or chemical compatibility of commonly used medications in critically ill patients with balanced crystalloids. Data sources: Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were queried from inception to September 2022. Study selection and data extraction: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. English-language studies reporting physical and/or chemical compatibility data between 50 selected medications and balanced crystalloids were included. A previously designed tool to assess risk of bias was adapted for use. Data synthesis: Twenty-nine studies encompassing 39 (78%) medications and 188 unique combinations with balanced crystalloids were included. Combinations included 35 (70%) medications with lactated Ringer’s, 26 (52%) medications with Plasma-Lyte, 10 (20%) medications with Normosol, and one (2%) medication with Isolyte. Studies commonly evaluated physical and chemical compatibility (55.2%). More medications were evaluated via Y-site than admixture. Incompatibilities were identified in 18% of combinations comprising 13 individual drugs. Relevance to patient care and clinical practice: This systematic review evaluates the compatibility of select critical care medications with balanced crystalloid solutions. Results may be used as a tool to guide clinicians on balanced crystalloid compatibility, potentially increasing ubiquitous use and reducing patient exposure to normal saline. Conclusion and relevance: Data are limited regarding chemical/physical compatibility of commonly used medications in critically ill patients with balanced crystalloids. Additional compatibility studies are warranted, particularly methodologically rigorous studies assessing Plasma-Lyte, Normosol, and Isolyte. Of the evaluated medications, there was a low frequency of incompatibilities with balanced crystalloids.

2024-03-01·Heliyon

Consumption of non-antibacterial drugs may have negative impact on Helicobacter pylori colonization in the stomach

Article

作者: Arven, Asadullah ; Foroumadi, Alireza ; Sadjadi, Alireza ; Kadkhodaei, Sara ; Siavoshi, Farideh ; Hatefi, Atousa ; Atif, Allah Nazar

BackgroundNineteen non-antibacterials were examined to show that their consumption for treatment of other diseases may inhibit Helicobacter pylori. Four antibiotics were used for comparison.Materials and methodsAgar dilution method was used to examine the susceptibility of 20 H. pylori isolates to 4 antibiotics; metronidazole (MTZ), clarithromycin (CLR), amoxicillin (AMX), tetracycline (TET) and 19 non-antibacterials; proton pump inhibitors (PPIs), H₂-blockers, bismuth subsalicylate (BSS), antifungals, statins, acetaminophen (ACE), aspirin (ASA), B-vitamins (B-Vits; Vit B1, Vit B6 and Vit B_complex) and vitamin C (Vit C). Blood agar plates were prepared with different concentrations of drugs and spot-inoculated with bacterial suspensions. Plates were incubated at 37 °C under microaerobic conditions and examined after 3-5 days. The isolate #20 that was mucoid and resistant to 19 drugs, including MTZ and SMV was tested against combined MTZ (8 μg/mL) and SMV (100 μg/mL). Results were analyzed statistically.ResultsMinimum inhibitory concentrations (MICs, μg/mL) of drugs and the frequency of susceptible H. pylori were determined as MTZ (8, 80%), CLR (2, 90%), AMX (1, 100%), TET (0.5, 70%), PPIs (8-128, 80%), H₂-blockers (2000-8000, 75-80%), BSS (15, 85%), antifungals (64-256, 30-80%), statins (100-250, 35-90%), ACE (40, 75%), ASA (800, 75%), B-Vits (5000-20000, 80-100%) and Vit C (2048, 85%). Susceptibility of H. pylori isolates to 16 out of 19 non-antimicrobials (75-100%) was almost similar to those of antibiotics (70-100%) (P-value >0.05). The highest susceptibility rate (100%) belonged to Vit B1, Vit B6 and AMX. Out of 20 H. pylori isolates, 17 (85%) were susceptible to ≥13 non-antimicrobials and 3 (15%) were susceptible to < 13 (P-value <0.05). Mucoid H. pylori showed susceptibility to combination of MTZ and SMV.ConclusionsMost of non-antibacterials inhibited H. pylori isolates, similar to antibiotics but their MICs exceeded those of antibiotics and their plasma concentrations. At low plasma concentration, non-antimicrobials may act as weak antibacterials, antibiotic adjuvants and immunostimulators.

100 项与氯化钙/氯化镁/氯化钾/醋酸钠/氯化钠/柠檬酸钠相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
眼科外科手术	美国	Alcon Laboratories, Inc.	1997-12-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01024803 (ARVO2012)	N/A	植入并发症	21	Silicone oil	蓋網壓鏇願憲衊壓壓廠(憲鬱鏇艱選壓醖願鹹蓋) = 繭壓淵選廠窪憲鹹製窪選醖鑰願醖膚廠夢襯築 (艱鹹鬱製構製願遞選顧 ) 更多	积极	2012-03-01
				BSS	蓋網壓鏇願憲衊壓壓廠(憲鬱鏇艱選壓醖願鹹蓋) = 鹽醖鹹範襯鹹簾繭鑰網選醖鑰願醖膚廠夢襯築 (艱鹹鬱製構製願遞選顧 ) 更多
ARVO2010	N/A	角膜上皮缺损	-	BSS	(襯齋憲簾鹹糧築鬱艱窪) = 醖夢築醖範鹽憲鑰淵鑰顧糧壓觸齋觸鏇獵觸夢 (範膚衊糧憲製範齋選蓋, 4.9)	不佳	2010-04-01
				Vigamox	(襯齋憲簾鹹糧築鬱艱窪) = 淵糧選鏇艱憲製糧憲壓顧糧壓觸齋觸鏇獵觸夢 (範膚衊糧憲製範齋選蓋, 4.1)
ARVO2009	N/A	-	-	Bevacizumab	範衊築繭簾簾選廠艱糧(鏇積繭積淵糧選遞築繭) = 製憲廠獵襯鏇窪壓網範壓窪繭艱廠齋顧衊選範 (憲範獵獵繭構襯簾構齋 ) 更多	-	2009-04-01
				Core Pars Plana Vitrectomy (cppV) + Bevacizumab + Dexamethasone	範衊築繭簾簾選廠艱糧(鏇積繭積淵糧選遞築繭) = 鹽醖蓋鏇簾鹹襯觸齋積壓窪繭艱廠齋顧衊選範 (憲範獵獵繭構襯簾構齋 ) 更多
ARVO2004	N/A	Nerve growth factor	-	Nerve growth factor (NGF) eye drops	(選繭鑰獵網窪網夢淵範) = 襯鹹鏇襯繭遞膚觸繭觸膚憲製鹽選襯廠淵淵鹹 (顧獵網衊窪壓齋衊蓋構 )	积极	2004-05-01
				BSS eye drops	(選繭鑰獵網窪網夢淵範) = 範夢鏇鹽製醖鹹網願夢膚憲製鹽選襯廠淵淵鹹 (顧獵網衊窪壓齋衊蓋構 )